Avelumab-Induced Scleroderma in a Patient with Metastatic Squamous Cell Carcinoma of the Lung
Immune checkpoint inhibitors are associated with a spectrum of cutaneous immune-related adverse events. While maculopapular eruptions are the most common cutaneous adverse event, scleroderma can rarely develop. Herein, we report a case of new-onset scleroderma associated with avelumab treatment in t...
Saved in:
Main Authors: | Jeffrey L. Dobrzynski, Blake E. Vest, Brian L. Swick |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-01-01
|
Series: | Case Reports in Dermatological Medicine |
Online Access: | http://dx.doi.org/10.1155/2022/5360113 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metastatic Squamous Cell Carcinoma of the Anus to the Lung Confirmed with Allelotyping
by: Rachel Roth, et al.
Published: (2014-01-01) -
Real-World Efficacy and Safety of Avelumab Plus Axitinib in Metastatic Renal Cell Carcinoma: Results from the Ambispective RAVE-Renal Study
by: Ilya Tsimafeyeu, et al.
Published: (2024-12-01) -
Final Analysis of Post‐Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan
by: Norio Nonomura, et al.
Published: (2025-01-01) -
Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma
by: Wen-Chen Tang, et al.
Published: (2023-07-01) -
Cell Proliferation Activity and Prognostic Index in Squamous Cell Lung Carcinoma
by: José Antonio Alvarez-Riesgo, et al.
Published: (1998-01-01)